Patheon Completes Intermediate Scale Processing Facility at its Cincinnati Plant

TORONTO, Canada, (October 9, 2008)  –  Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry is pleased to announce the expansion of services utilizing a new Intermediate Scale Processing Suite (ISPS), located at the Cincinnati, Ohio facility. The ISPS provides increased manufacturing capacity that will bridge the gap between Patheon’s development and commercial scale facilities.

The new ISPS equipment includes an intermediate scale Diosna-P300 high shear granulator coupled with Niro-MP4 fluid bed dryer with solvent and high potency compound handling capabilities.  This added suite will allow the production of batch sizes ranging from 35-115 kg.  The ISPS will allow Patheon to meet the Development, Clinical, Registration, Scale-up, Validation and Commercial requirements for customers.  The expansion of services will also help to develop robust processes as projects move from development to commercial using statistical design of experiments, to support the FDA’s Quality by Design (QBD) initiative.  The ISPS provides greater flexibility in scheduling experiments on a larger scale and uses less active pharmaceutical ingredients (API) compared to commercial scale.

Terry Novak, President, North America and Chief Marketing Officer, at Patheon stated “The ISPS provides us with another valuable service to address the unique needs of our customers. By adding this equipment we will be able to reduce time and resources it takes to moving a new product though development.”

ABOUT PATHEON
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.  Patheon prides itself in providing the highest quality products and services to more than 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms.  Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies. 

Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.  Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.  Patheon’s integrated network strives to ensure that customer products can be launched with confidence globally.

Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect management’s expectations regarding the Company’s future growth of operations, performance (both operational and financial) and business prospects and opportunities.  These statements are made in the context of the risks and uncertainties that are outlined in the Company’s public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts: